Anticancer Mechanisms

Mebendazole is a repurposed-drug candidate because it does not rely on one mechanism alone. It appears to interfere with several core cancer survival systems at once.

Primary mechanisms

1. Tubulin polymerisation inhibition

• disrupts microtubule formation

• arrests cell division

• acts through a classic anti-mitotic mechanism relevant to proliferating tumour cells

2. Anti-angiogenic activity

• inhibits VEGFR2-related signalling

• reduces microvessel density in tumour models

• suppresses tumour blood-vessel formation

3. Akt, NF-κB, and β-catenin pathway inhibition

• suppresses key survival and inflammatory signalling

• reduces metastatic and proliferative behaviour

• supports apoptosis and reduced resistance potential

4. HIF suppression

• disrupts tumour hypoxia-response signalling

• relevant in aggressive and treatment-resistant tumour biology

• especially interesting in breast and hypoxia-driven models

5. Apoptosis induction

• promotes programmed cell death in multiple cancer models

• can work alongside cell-cycle arrest and anti-angiogenic stress

6. ERK / MAPK modulation

• inhibits ERK signalling in cancer cells

• may activate ERK-related immune signalling in immune cells, supporting anti-tumour responses

• this dual behaviour makes it mechanistically distinctive among repurposed and natural adjuncts

TP53 context

Mebendazole appears less dependent on intact p53 than fenbendazole.

It has shown activity in wild-type, mutant, and null p53 settings.

Read the full breakdown in Mebendazole and TP53.

We also have a section dedicated to learning about TP53.

There, you can explore how different drugs and natural compounds may be influenced by TP53 status, or may influence TP53-related biology.

Start with TP53 in Cancer Overview.

Practical interpretation

This broad mechanism profile is one reason mebendazole remains one of the most compelling low-cost repurposing candidates in oncology.

Key References

Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/

Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines
https://pmc.ncbi.nlm.nih.gov/articles/PMC11763501/

Repurposing of Mebendazole as an Anticancer Agent: A Review
https://rjptonline.org/HTMLPaper.aspx